MAPT and Cognitive impairment: However, clinical drug candidate developments targeting Aβ and Tau have struggled to produce positive results.[7] Recently, it has been reported that microglia activation‐induced neuroinflammation is more prevalent in older adults and is more pronounced in patients with cognitive impairment and AD‐related dementia,[22] indicating that activated microglia‐mediated neuroinflammation may play a crucial role in the occurrence and development of AD.